fbpx
Regeneron's Monoclonal antibodies for treatment of COVID-19 Coronavirus Approved by FDA

ERG Clinical Trial Sites Contribute to Approval of Regeneron’s COVID-19 Treatment

With COVID-19 cases rising at alarming rates across the US, Emergency Use Authorization of Regeneron’s COVID treatment couldn’t have come soon enough.  The FDA announced late last month that casirivimab and imdevimab, two monoclonal antibodies, were authorized for emergency use in patients with mild and moderate Coronavirus Disease 2019. Clinical trials demonstrated that the two …

Read moreERG Clinical Trial Sites Contribute to Approval of Regeneron’s COVID-19 Treatment

COVID-19 INFO

The health of our staff members, study participants and visitors is of the utmost importance to us.